A meta-analysis of the efficacy and safety of montelukast sodium in combination with budesonide nasal spray in the treatment of allergic rhinitis

OBJECTIVE To systematically evaluate the efficacy and safety of montelukast sodium combined with budesonide nasal spray in the treatment of allergic rhinitis. METHODS Databases such as China Biomedical Literature Database, China Knowledge Network, Wanfang Database, VIP Database, Embase, Cochrane Library, Pubmed, and Web Of Science were searched. Randomized controlled trials evaluating montelukast sodium in combination with budesonide nasal spray for allergic rhinitis were included to be searched from the date of database construction to March 18, 2023. Meta-analysis was performed using RevMan 5. 4 software after data extraction by 2 investigators, selection of literature, and evaluation of the risk of bias of included articles. Results: A total of 16 RCTs including 1277 patients, 638 patients in the study group, and 639 patients in the control group, were included in the study. 0.00001), significant rate (OR = 2.29,95%CI = 1.77 ~ 2.96,P < 0.00001), nasal symptom score (SMD=-1.41,95%CI=-2.30~-0.53,P < 0.00001), interleukin 6 level (MD= -36.06 ,95%CI = − 41.80~ -30.33 ,P < 0.00001 ), interleukin 8 (MD= -24.30,95%CI= -29.71~ -18.89,P < 0.00001) and interleukin 10 (MD = 3.77,95%CI = 3.36 ~ 4.17,P < 0.00001) were significantly The differences were statistically significant. The differences in the incidence of adverse reactions between the study group and the control group were not statistically significant (OR = 0.53,95%CI = 0.16 ~ 1.72, P = 0.29 ). Conclusion: Montelukast sodium combined with budesonide nasal spray is more effective than budesonide nasal spray alone in the treatment of allergic rhinitis.